Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Tables)

v3.21.1
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2020
Stockholders' Equity  
Stock Based Compensation Plans of Partner Companies

Certain partner companies have their own equity compensation plan under which shares are granted to eligible employees, directors and consultants in the form of restricted stock, stock options, and other types of grants of stock of the respective partner company’s common stock. The table below provides a summary of those plans as of December 31, 2020:

​

​

​

​

​

​

​

​

Partner

​

​

​

Shares

​

Shares available at

Company

    

Stock Plan

    

Authorized

    

December 31, 2020

Aevitas

​

Aevitas Therapeutics, Inc. 2018 Long Term Incentive Plan

​

2,000,000

​

1,602,000

Avenue

 

Avenue Therapeutics, Inc. 2015 Stock Plan

 

2,000,000

 

229,436

Baergic

 

FBIO Acquisition Corp. III 2017 Incentive Plan

 

2,000,000

 

1,150,000

Cellvation

 

Cellvation Inc. 2016 Incentive Plan

 

2,000,000

 

300,000

Checkpoint

 

Checkpoint Therapeutics, Inc. Amended and Restated 2015 Stock Plan

 

9,000,000

 

4,288,465

Cyprium

 

Cyprium Therapeutics, Inc. 2017 Stock Plan

 

2,000,000

 

575,000

Helocyte

 

DiaVax Biosciences, Inc. 2015 Incentive Plan

 

2,000,000

 

341,667

Journey

 

Journey Medical Corporation 2015 Stock Plan

 

3,642,857

 

34,000

Mustang

 

Mustang Bio, Inc. 2016 Incentive Plan

 

5,000,000

 

1,180,085

Oncogenuity, Inc.

​

FBIO Acquisition Corp. VII 2017 Incentive Plan

​

2,000,000

​

1,600,000

Tamid

 

FBIO Acquisition Corp. V 2017 Incentive Plan

 

2,000,000

 

1,600,000

Schedule of Stock-Based Compensation Expense

The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the years ended December 31, 2020 and 2019

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

($ in thousands)

    

2020

    

2019

Employee awards

​

$

4,991

​

$

3,666

Executive awards of Fortress Companies' stock

​

 

1,504

​

 

1,428

Non-employee awards

​

 

159

​

 

121

Warrants

​

​

130

​

​

97

Partner Companies:

​

​

​

​

​

​

Avenue

​

 

710

​

 

1,839

Checkpoint

​

 

2,780

​

 

3,121

Mustang

​

 

2,987

​

 

2,664

Other

​

 

190

​

 

252

Total stock-based compensation expense

​

$

13,451

​

$

13,188

Schedule of Stock Option Activities

The following table summarizes Fortress stock option activities excluding activities related to partner companies:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted average

​

​

​

​

​

​

​

Total

​

remaining

​

​

​

​

Weighted average

​

weighted average

​

contractual life

​

    

Shares

    

exercise price

    

intrinsic value

    

(years)

Options vested and expected to vest at December 31, 2018

​

1,285,501

​

$

3.75

​

$

—

​

2.93

Granted

​

125,000

​

​

1.18

​

​

173,750

​

​

Options vested and expected to vest at December 31, 2019

 

1,410,501

​

$

4.30

​

$

684,752

 

2.33

Exercised

 

(100,000)

​

​

1.18

​

 

—

 

—

Forfeited

​

(257,011)

​

​

2.57

​

​

—

​

—

Options vested and expected to vest at December 31, 2020

 

1,053,490

​

$

5.02

​

$

647,482

 

2.63

Schedule of Restricted Stock Awards and Restricted Stock Units

The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress subsidiaries:

​

​

​

​

​

​

​

​

    

​

    

Weighted

​

​

​

​

average grant

​

​

Number of shares

​

price

Unvested balance at December 31, 2018

 

12,645,982

​

$

2.72

Restricted stock granted

 

1,546,408

​

 

0.88

Restricted stock vested

 

(220,000)

​

 

3.16

Restricted stock units granted

​

290,000

​

​

1.49

Restricted stock units forfeited

 

(135,416)

​

 

3.91

Restricted stock units vested

 

(358,960)

​

 

3.61

Unvested balance at December 31, 2019

​

13,768,014

​

$

2.46

Restricted stock granted

​

1,873,072

​

​

2.57

Restricted stock vested

​

(230,000)

​

​

2.78

Restricted stock units granted

​

630,126

​

​

3.82

Restricted stock units forfeited

​

(148,750)

​

​

3.30

Restricted stock units vested

​

(384,958)

​

​

3.49

Unvested balance at December 31, 2020

​

15,507,504

​

$

2.49

Schedule of Warrant activities

The following table summarizes Fortress warrant activities, excluding activities related to partner companies:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Total weighted

​

Weighted average

​

​

​

​

​

​

​

average

​

remaining

​

​

Number of

​

Weighted average

​

 intrinsic

​

contractual life

​

    

shares

    

exercise price

    

value

    

(years)

Outstanding as of December 31, 2018

 

2,754,189

​

$

3.28

​

$

—

​

3.49

Granted

​

60,000

​

​

1.92

​

​

39,000

​

—

Forfeited

​

(73,009)

​

 

5.65

​

 

—

​

—

Outstanding as of December 31, 2019

 

2,741,180

​

$

3.19

​

$

111,000

 

2.73

Granted

 

1,849,450

​

 

3.14

​

 

101,000

 

—

Forfeited

 

(9)

​

 

3.00

​

 

2

 

—

Outstanding as of December 31, 2020

 

4,590,621

​

$

3.17

​

$

607,848

 

4.85

Exercisable as of December 31, 2020

 

4,430,621

​

$

3.21

​

$

452,848

 

4.80